Is the APOB rs1367117 variant associated with higher LDL-C and ApoB levels?

The association between genetic variation in the APOB gene and lipid profiles is a cornerstone of cardiovascular genomics. The rs1367117 variant, located within the APOB locus on chromosome 2p24.1, is frequently identified in genome-wide association studies (GWAS) as a significant marker for variation in cholesterol metabolism.

Clinical and population evidence

Population-based genetic research consistently links common variants in the APOB gene to phenotypic differences in low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (ApoB) levels.

• Large-scale meta-analyses, such as those conducted by the Global Lipids Genetics Consortium (GLGC), have identified rs1367117 as a lead single nucleotide polymorphism (SNP) associated with elevated lipid traits.
• The variant is recognized as an influential genetic factor in determining the concentration of ApoB-containing lipoproteins, which are primary drivers of atherosclerotic risk.
• While the specific magnitude of effect (beta coefficient) can vary by ancestry, the direction of the association—where specific alleles correlate with higher LDL-C—is well-documented across diverse cohorts.

Mechanistic explanations

The biological plausibility of this association is rooted in the fundamental role of Apolipoprotein B in lipid transport.

• Protein Function: The APOB gene encodes the structural protein required for the assembly of very-low-density lipoproteins (VLDL) in the liver and serves as the essential ligand for the LDL receptor (LDLR).
• Particle Clearance: Genetic variants like rs1367117 may alter the expression or functional characteristics of the ApoB protein. Variations that reduce the binding affinity of ApoB to the LDLR lead to impaired clearance of LDL particles from the plasma, resulting in elevated circulating LDL-C levels.
• Lipoprotein Metabolism: Because each LDL particle contains exactly one molecule of ApoB, the concentration of ApoB provides an indirect measure of the total number of atherogenic particles. Variants in this locus directly impact the steady-state concentration of these particles by modulating their production or removal rates.

Bottom line

The APOB rs1367117 variant is a plausible genetic driver of elevated LDL-C and ApoB levels in population studies. For a 45-year-old female, the presence of such variants may contribute to a higher polygenic risk for dyslipidemia, emphasizing the importance of monitoring ApoB as a more precise marker of cardiovascular risk than LDL-C alone.